Direxion Daily S&P Biotech Bull 3X Shares (LABU)
ARCA ARCA Primary 
XMEX Summary
LABU Chart
LABU Could Rip Higher if Biotech Finally Gets Its Long-Awaited Breakout
If you bought XBI a year ago and held it, you are up roughly 65%. If you bought Direxion Daily S&P Biotech Bull 3X Shares (NYSEARCA:LABU) on the same day, you are up about 235%.
Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU) Shares Gap Down – Here’s Why
Direxion Daily S&P Biotech Bull 3x Shares (NYSEARCA:LABU - Get Free Report) gapped down prior to trading on Friday. The stock had previously closed at $170.74, but opened at $164.08. Direxion Daily S&P Biotech Bull 3x Shares shares last traded at $165.2680, with a volume of 83,975 shares traded. Direxion Daily S&P Biotech Bull
Triple-Leveraged Biotech ETF Doubles as Regulatory Winds Shift in 2026
Triple-leveraged ETFs aren't for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull 3X Shares (NASDAQ:LABU) offers the most aggressive way to capture that move.
Direxion Daily S&P Biotech Bull 3X Shares Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JA Jeff Ameen Spire Wealth Management | 1,109 | $88,327.77 | $193,287.61 | $104,959.84 | 118.83% |
| AI Ana-Maria Ignat Covestor Ltd | 448 | $71,406.72 | $78,247.68 | $6,840.96 | 9.58% |
| DG Daniel Guy Ethos Financial Group LLC | 3,915 | $229,481.23 | $685,751.4 | $456,270.17 | 198.83% |
Direxion Daily S&P Biotech Bull 3X Shares (LABU) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Direxion Daily S&P Biotech Bull 3X Shares ever had a stock split?
Direxion Daily S&P Biotech Bull 3X Shares Profile
| ARCA Exchange | US Country |
Overview
The company described operates within the financial industry, focusing primarily on offering investment solutions that provide leveraged exposure to the biotechnology sub-industry. It is designed for investors looking to maximize their investment in the biotechnology sector through the use of financial instruments that aim to amplify the daily performance of the biotechnology index. This fund employs a strategy that involves investing a significant portion of its assets in derivatives and exchange-traded funds (ETFs) that are linked to the performance of the biotechnology index as defined by the Global Industry Classification Standards (GICS). This approach allows the fund to offer thrice the daily leveraged exposure to its investors, making it an aggressive investment choice suitable for those with a higher risk tolerance. The fund is characterized as non-diversified, meaning it concentrates its investments more narrowly than diversified funds."
Products and Services
In offering targeted financial solutions, the company provides investors with high-risk, high-reward investment opportunities in the biotechnology sector. Below are the primary products and services offered:
- Swap Agreements: These are derivative contracts through which two parties exchange financial instruments or cash flows, based on the underlying biotechnology index performance. Swap agreements are crucial for the fund in achieving its goal of 3X daily leveraged exposure to the biotechnology sector.
- Securities of the Index: Investing directly in securities that constitute the biotechnology index allows the fund to closely track the performance of the biotechnology sub-industry. This includes stocks of companies operating in biotechnological research, development, and manufacturing, as classified by the GICS.
- ETFs that Track the Index: The fund invests in Exchange-Traded Funds (ETFs) that replicate the performance of the biotechnology index. These ETFs provide an additional layer of exposure to the sector, enabling investors to benefit from the aggregated performance of the biotechnology companies included in the index.
